Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$8.82
0.303.52%
At close: Jul 14, 5:00 PM EST
$8.82
N/A
After Hours: 4:00 PM EST
BridgeBio Oncology Therapeutics Inc Analyst Ratings
BBOTNASDAQ
BridgeBio Oncology Analyst Ratings and Price Targets | NASDAQ:BBOT | Benzinga
BridgeBio Oncology Therapeutics Inc has a consensus price target of $24 based on the ratings of 10 analysts. The high is $29 issued by HC Wainwright & Co. on March 6, 2026. The low is $20 issued by Morgan Stanley on December 5, 2025. The 3 most-recent analyst ratings were released by JP Morgan, Oppenheimer, and Canaccord Genuity on July 8, 2026, June 22, 2026, and May 11, 2026, respectively. With an average price target of $24 between JP Morgan, Oppenheimer, and Canaccord Genuity, there's an implied 172.11% upside for BridgeBio Oncology Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Oppenheimer
Canaccord Genuity
HC Wainwright & Co.
Stifel
1calculated from analyst ratings
Analyst Ratings for BridgeBio Oncology
Loading calendar...
FAQ
What is the target price for BridgeBio Oncology (BBOT) stock?
The latest price target for BridgeBio Oncology (NASDAQ:BBOT) was reported by JP Morgan on July 8, 2026. The analyst firm set a price target for $27.00 expecting BBOT to rise to within 12 months (a possible 206.12% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BridgeBio Oncology (BBOT)?
The latest analyst rating for BridgeBio Oncology (NASDAQ:BBOT) was provided by JP Morgan, and BridgeBio Oncology initiated their overweight rating.
When was the last upgrade for BridgeBio Oncology (BBOT)?
There is no last upgrade for BridgeBio Oncology
When was the last downgrade for BridgeBio Oncology (BBOT)?
There is no last downgrade for BridgeBio Oncology.
When is the next analyst rating going to be posted or updated for BridgeBio Oncology (BBOT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Oncology was filed on July 8, 2026 so you should expect the next rating to be made available sometime around July 8, 2027.
Is the Analyst Rating BridgeBio Oncology (BBOT) correct?
While ratings are subjective and will change, the latest BridgeBio Oncology (BBOT) rating was a initiated with a price target of $0.00 to $27.00. The current price BridgeBio Oncology (BBOT) is trading at is $8.82, which is within the analyst’s predicted range.
